JP2005506345A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506345A5 JP2005506345A5 JP2003535710A JP2003535710A JP2005506345A5 JP 2005506345 A5 JP2005506345 A5 JP 2005506345A5 JP 2003535710 A JP2003535710 A JP 2003535710A JP 2003535710 A JP2003535710 A JP 2003535710A JP 2005506345 A5 JP2005506345 A5 JP 2005506345A5
- Authority
- JP
- Japan
- Prior art keywords
- tfpi
- pharmaceutical composition
- analog
- administration
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 62
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims 46
- 108010013555 lipoprotein-associated coagulation inhibitor Chemical class 0.000 claims 46
- 238000001990 intravenous administration Methods 0.000 claims 5
- 229940024606 amino acid Drugs 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 208000026425 severe pneumonia Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000001802 infusion Methods 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 1
- 102000002262 Thromboplastin Human genes 0.000 claims 1
- 108010000499 Thromboplastin Proteins 0.000 claims 1
- -1 antibodies Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229960003589 arginine hydrochloride Drugs 0.000 claims 1
- 102000052586 bactericidal permeability increasing protein Human genes 0.000 claims 1
- 108010032816 bactericidal permeability increasing protein Proteins 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000004074 complement inhibitor Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32880601P | 2001-10-15 | 2001-10-15 | |
| PCT/US2002/032624 WO2003032904A2 (en) | 2001-10-15 | 2002-10-15 | Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005271219A Division JP2006008706A (ja) | 2001-10-15 | 2005-09-16 | 組織因子経路インヒビター（ｔｆｐｉ）の投与による重症な肺炎の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506345A JP2005506345A (ja) | 2005-03-03 |
| JP2005506345A5 true JP2005506345A5 (OSRAM) | 2006-01-05 |
Family
ID=23282520
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003556020A Withdrawn JP2005515214A (ja) | 2001-10-15 | 2002-10-15 | 組織因子経路インヒビター（ｔｆｐｉ）の低量投与による敗血症の処置 |
| JP2003535710A Withdrawn JP2005506345A (ja) | 2001-10-15 | 2002-10-15 | 組織因子経路インヒビター（ｔｆｐｉ）の投与による重症な肺炎の処置 |
| JP2005271191A Withdrawn JP2006008704A (ja) | 2001-10-15 | 2005-09-16 | 組織因子経路インヒビター（ｔｆｐｉ）の低量投与による敗血症の処置 |
| JP2005271219A Pending JP2006008706A (ja) | 2001-10-15 | 2005-09-16 | 組織因子経路インヒビター（ｔｆｐｉ）の投与による重症な肺炎の処置 |
| JP2009235793A Withdrawn JP2010006839A (ja) | 2001-10-15 | 2009-10-09 | 組織因子経路インヒビター（ｔｆｐｉ）の低量投与による敗血症の処置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003556020A Withdrawn JP2005515214A (ja) | 2001-10-15 | 2002-10-15 | 組織因子経路インヒビター（ｔｆｐｉ）の低量投与による敗血症の処置 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005271191A Withdrawn JP2006008704A (ja) | 2001-10-15 | 2005-09-16 | 組織因子経路インヒビター（ｔｆｐｉ）の低量投与による敗血症の処置 |
| JP2005271219A Pending JP2006008706A (ja) | 2001-10-15 | 2005-09-16 | 組織因子経路インヒビター（ｔｆｐｉ）の投与による重症な肺炎の処置 |
| JP2009235793A Withdrawn JP2010006839A (ja) | 2001-10-15 | 2009-10-09 | 組織因子経路インヒビター（ｔｆｐｉ）の低量投与による敗血症の処置 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7674769B2 (OSRAM) |
| EP (2) | EP1446138A4 (OSRAM) |
| JP (5) | JP2005515214A (OSRAM) |
| KR (2) | KR20040040489A (OSRAM) |
| CN (2) | CN1604790A (OSRAM) |
| AU (2) | AU2002365131B2 (OSRAM) |
| BR (2) | BR0213292A (OSRAM) |
| CA (2) | CA2463655A1 (OSRAM) |
| EA (2) | EA200400548A1 (OSRAM) |
| HU (2) | HUP0501111A2 (OSRAM) |
| IL (2) | IL161407A0 (OSRAM) |
| IS (2) | IS7223A (OSRAM) |
| MX (2) | MXPA04003547A (OSRAM) |
| NO (2) | NO20041997D0 (OSRAM) |
| PL (2) | PL372138A1 (OSRAM) |
| WO (2) | WO2003055442A2 (OSRAM) |
| ZA (2) | ZA200403601B (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200400548A1 (ru) * | 2001-10-15 | 2005-06-30 | Чирон Корпорейшн | Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi) |
| WO2004062646A1 (en) * | 2003-01-08 | 2004-07-29 | Chiron Corporation | Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
| EP1654283B1 (en) * | 2003-08-13 | 2011-07-13 | Novartis Vaccines and Diagnostics, Inc. | Improved method of purifying tfpi and tfpi analogs |
| EP1729791A2 (en) * | 2004-03-17 | 2006-12-13 | Chiron Corporation | Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi) |
| CN101180074A (zh) * | 2005-04-15 | 2008-05-14 | 诺华疫苗和诊断公司 | 通过施用组织因子通路抑制剂(tfpi)治疗严重社区获得性肺炎 |
| CA2607293A1 (en) * | 2005-05-06 | 2006-11-16 | Novartis Ag | Use of tfpi to treat severe bacterial infections |
| NZ595225A (en) | 2005-05-16 | 2013-05-31 | Abbott Biotech Ltd | Use of tnf inhibitor for treatment of erosive polyarthritis |
| US20100297099A1 (en) * | 2005-06-24 | 2010-11-25 | Lars Otto Uttenthal | Airway Administration of Activated Protein C in Inflammatory Conditions Affecting the Respiratory Tract |
| KR20080040676A (ko) * | 2005-07-22 | 2008-05-08 | 노파르티스 아게 | 항미생물제로서의 ｔｆｐｉ 단편 |
| WO2008063213A2 (en) | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
| US20110142837A1 (en) * | 2007-07-20 | 2011-06-16 | Trustees Of The University Of Pennsylvania | Method Of Treating Acute Respiratory Distress Syndrome |
| WO2009129164A1 (en) * | 2008-04-15 | 2009-10-22 | Novartis Ag | Pharmaceutical combinations of tfpi-fragments and an antibiotic |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| WO2012078968A2 (en) | 2010-12-10 | 2012-06-14 | Lifeline Scientific, Inc. | Machine perfusion with complement inhibitors |
| CA2841013C (en) | 2011-07-18 | 2020-04-21 | Morphosys Ag | Use of c-fms antagonists |
| KR101672108B1 (ko) | 2011-11-15 | 2016-11-02 | 아사히 가세이 파마 가부시키가이샤 | 패혈증의 치료 및/또는 개선을 위한 의약 |
| EP2984106B1 (en) | 2013-04-12 | 2019-03-06 | MorphoSys AG | Antibodies targeting m-csf |
| US11908581B2 (en) | 2018-04-10 | 2024-02-20 | Hill-Rom Services, Inc. | Patient risk assessment based on data from multiple sources in a healthcare facility |
| US11504071B2 (en) | 2018-04-10 | 2022-11-22 | Hill-Rom Services, Inc. | Patient risk assessment based on data from multiple sources in a healthcare facility |
| CN118715235A (zh) * | 2022-01-30 | 2024-09-27 | 西湖大学 | 预防和/或治疗由分支2菌株引起的艰难梭菌感染的组合物和方法 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4603106A (en) * | 1982-02-22 | 1986-07-29 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| JPS5896026A (ja) * | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3219248A1 (de) | 1982-05-21 | 1983-11-24 | Solco Basel AG, Birsfelden | Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut |
| EP0098110B1 (en) * | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4620948A (en) * | 1982-12-22 | 1986-11-04 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4511502A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4711845A (en) * | 1984-08-31 | 1987-12-08 | Cetus Corporation | Portable temperature-sensitive control cassette |
| US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US4530787A (en) * | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| JPS61502166A (ja) | 1984-04-19 | 1986-10-02 | アグラシタス | 植物細胞の形質転換のための改良された方法及びベクタ− |
| US4572798A (en) * | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
| US4847201A (en) * | 1985-02-05 | 1989-07-11 | Cetus Corporation | DNA encoding for CSF-1 and accompanying recombinant systems |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4748234A (en) * | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| US5110730A (en) * | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
| US5223427A (en) * | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
| US4929700A (en) * | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
| US4966852A (en) * | 1987-07-23 | 1990-10-30 | Monsanto Company | DNA clone of human tissue factor inhibitor |
| US5106833A (en) * | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
| IL87171A (en) | 1987-11-23 | 1995-08-31 | Monsanto Co | cDNA of human tissue factor inhibitor |
| US5219994A (en) * | 1988-11-08 | 1993-06-15 | W. Alton Jones Cell Science Center, Inc. | Inhibitor of tissue factor activity |
| DK412389D0 (da) | 1989-01-19 | 1989-01-19 | Novo Nordisk As | Fremgangsmaade til udvinding af oprenset epi protein fra en fermenteringsoploesning |
| DK408089D0 (da) | 1989-08-18 | 1989-08-18 | Novo Nordisk As | Proteiner |
| DK148890D0 (da) | 1990-06-19 | 1990-06-19 | Novo Nordisk As | Farmaceutisk praeparat |
| IE913004A1 (en) | 1990-08-27 | 1992-03-11 | Monsanto Co | Anticoagulant combination of laci and sulfated¹polysaccharides |
| US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| DK261490D0 (da) | 1990-10-31 | 1990-10-31 | Novo Nordisk As | New pharmaceutical compound |
| US5212091A (en) * | 1992-03-02 | 1993-05-18 | Monsanto Company | Method of producing tissue factor pathway inhibitor |
| US5276015A (en) | 1992-03-18 | 1994-01-04 | Washington University | Method of inhibiting microvascular thrombosis |
| USRE36476E (en) | 1992-03-18 | 1999-12-28 | Washington University | Method of inhibiting microvascular thrombosis |
| WO1993024143A1 (en) * | 1992-06-01 | 1993-12-09 | Cetus Oncology Corporation | A method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| AU4408493A (en) | 1992-06-11 | 1994-01-04 | Washington University | Prophylaxis and treatment of sepsis and sepsis-associated coagulation disorders |
| US5589359A (en) * | 1994-08-05 | 1996-12-31 | Chiron Corporation | Chimeric proteins |
| JP3571378B2 (ja) * | 1994-09-30 | 2004-09-29 | 扶桑薬品工業株式会社 | 感染症診断用プローブ |
| JP3761914B2 (ja) * | 1994-11-17 | 2006-03-29 | 財団法人化学及血清療法研究所 | アンチトロンビンｉｉｉ及び組織因子凝固系インヒビター含有血栓症治療剤 |
| US5914316A (en) | 1994-12-16 | 1999-06-22 | Washington University | Method of inhibiting intimal hyperplasia |
| US5612363A (en) | 1995-06-02 | 1997-03-18 | Berlex Laboratories, Inc. | N,N-di(aryl) cyclic urea derivatives as anti-coagulants |
| US5888968A (en) | 1995-06-07 | 1999-03-30 | Chiron Corporation | TFPI formulation |
| US6242414B1 (en) | 1995-06-07 | 2001-06-05 | Chiron Corporation | Regulation of cytokine synthesis and release |
| US5885781A (en) | 1995-06-07 | 1999-03-23 | Chiron Corporation | Regulation of cytokine synthesis and release |
| DK1602667T3 (da) | 1995-06-07 | 2007-07-23 | Novartis Vaccines & Diagnostic | Vandig formulering omfattende TFPI og solubiliseringsmidler |
| US5902582A (en) | 1995-09-05 | 1999-05-11 | Chiron Corporation | Use of TFPI inhibitor for treatment of cancer |
| US5772629A (en) * | 1995-10-23 | 1998-06-30 | Localmed, Inc. | Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels |
| US5736364A (en) | 1995-12-04 | 1998-04-07 | Genentech, Inc. | Factor viia inhibitors |
| KR100442758B1 (ko) | 1996-03-25 | 2004-10-06 | 사이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 조직인자응고계억제제함유혈관신생저해제 |
| US5977057A (en) * | 1996-05-08 | 1999-11-02 | The University Of Vermont And State Agricultural College | Thrombosis prophylaxis for factor VLEIDEN carriers |
| AU6042298A (en) * | 1997-01-31 | 1998-08-25 | Human Genome Sciences, Inc. | Tissue factor pathway inhibitor-3 |
| US5981471A (en) | 1997-02-06 | 1999-11-09 | Entremed, Inc. | Compositions and methods for inhibiting cellular proliferation |
| AR015598A1 (es) | 1997-04-28 | 2001-05-16 | Lilly Co Eli | FORMULACIoN LIOFILIZADA QUE COMPRENDE PROTEíNA C ACTIVADA, SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO Y FORMA DE DOSIS UNITARIA QUE LA COMPRENDE. |
| IL121191A0 (en) | 1997-06-29 | 1997-11-20 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
| HUP0001237A3 (en) | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| US6824997B1 (en) * | 1998-09-18 | 2004-11-30 | Binax, Inc. | Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies |
| BR9914735A (pt) | 1998-10-22 | 2001-07-03 | Lilly Co Eli | Processo para tratamento de sépsia |
| DE69906568T2 (de) | 1998-11-20 | 2004-02-12 | Eli Lilly And Co., Indianapolis | Behandlung von hämorrhagischem virusfieber mit protein c |
| WO2000077254A1 (en) * | 1999-06-11 | 2000-12-21 | The Government Of The United States Of America As Represented By The Secretary, Of The Department Of Health And Human Services | Detection of streptococcus pneumoniae and immunization against streptococcus pneumoniae infection |
| WO2000077246A2 (en) | 1999-06-14 | 2000-12-21 | Novo Nordisk A/S | A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS |
| US6294648B1 (en) | 1999-07-20 | 2001-09-25 | Bayer Corporation | Protein having proteinase inhibitor activity |
| US6180607B1 (en) | 1999-08-05 | 2001-01-30 | Christopher Davies | Protein having proteinase inhibitor activity |
| CN1245216C (zh) | 1999-10-04 | 2006-03-15 | 希龙公司 | 稳定化的含多肽的液体药物组合物 |
| AU2908501A (en) | 2000-01-06 | 2001-07-16 | Eli Lilly And Company | Combination therapy for the treatment of inflammatory and respiratory diseases |
| JP2003521938A (ja) | 2000-02-11 | 2003-07-22 | イーライ・リリー・アンド・カンパニー | プロテインｃ誘導体 |
| HK1053972A1 (zh) | 2000-02-16 | 2003-11-14 | Northwestern University | 聚甘氨酸胺基取代的阳离子寡聚合物肺表面活性剂 |
| DE10022092A1 (de) | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| US7015194B2 (en) | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
| DE60217835D1 (en) | 2001-02-28 | 2007-03-15 | John H Griffin | Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c |
| EP1383885A4 (en) | 2001-04-04 | 2005-11-30 | American Diagnostica Inc | METHOD FOR PRODUCING A STABILIZED THROMBIN-ACTIVATED FIBRINOLYSE INHIBITOR (TAFI) AND METHOD FOR THE USE THEREOF |
| DE10132307A1 (de) | 2001-07-06 | 2003-01-30 | Aventis Behring Gmbh | Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS |
| EA200400548A1 (ru) | 2001-10-15 | 2005-06-30 | Чирон Корпорейшн | Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi) |
| US20020198138A1 (en) | 2002-06-07 | 2002-12-26 | Macias William Louis | Combination therapy for the treatment of inflammatory and respiratory diseases |
-
2002
- 2002-10-15 EA EA200400548A patent/EA200400548A1/ru unknown
- 2002-10-15 EA EA200400549A patent/EA200400549A1/ru unknown
- 2002-10-15 KR KR10-2004-7005632A patent/KR20040040489A/ko not_active Withdrawn
- 2002-10-15 EP EP02803284A patent/EP1446138A4/en not_active Withdrawn
- 2002-10-15 WO PCT/US2002/032625 patent/WO2003055442A2/en not_active Ceased
- 2002-10-15 JP JP2003556020A patent/JP2005515214A/ja not_active Withdrawn
- 2002-10-15 BR BRPI0213292-3A patent/BR0213292A/pt unknown
- 2002-10-15 AU AU2002365131A patent/AU2002365131B2/en not_active Ceased
- 2002-10-15 HU HU0501111A patent/HUP0501111A2/hu unknown
- 2002-10-15 KR KR1020047005618A patent/KR20050036867A/ko not_active Withdrawn
- 2002-10-15 IL IL16140702A patent/IL161407A0/xx unknown
- 2002-10-15 CA CA002463655A patent/CA2463655A1/en not_active Abandoned
- 2002-10-15 MX MXPA04003547A patent/MXPA04003547A/es unknown
- 2002-10-15 AU AU2002340183A patent/AU2002340183B2/en not_active Ceased
- 2002-10-15 EP EP02778529A patent/EP1446140A4/en not_active Withdrawn
- 2002-10-15 JP JP2003535710A patent/JP2005506345A/ja not_active Withdrawn
- 2002-10-15 US US10/270,478 patent/US7674769B2/en not_active Expired - Fee Related
- 2002-10-15 HU HU0500472A patent/HUP0500472A2/hu unknown
- 2002-10-15 PL PL02372138A patent/PL372138A1/xx not_active Application Discontinuation
- 2002-10-15 WO PCT/US2002/032624 patent/WO2003032904A2/en not_active Ceased
- 2002-10-15 CN CNA028249003A patent/CN1604790A/zh active Pending
- 2002-10-15 PL PL02374506A patent/PL374506A1/xx not_active Application Discontinuation
- 2002-10-15 CA CA002463738A patent/CA2463738A1/en not_active Abandoned
- 2002-10-15 CN CNA028250648A patent/CN1604787A/zh active Pending
- 2002-10-15 IL IL16140802A patent/IL161408A0/xx unknown
- 2002-10-15 BR BR0213293-1A patent/BR0213293A/pt not_active Application Discontinuation
-
2003
- 2003-02-04 US US10/270,479 patent/US20030139340A1/en not_active Abandoned
-
2004
- 2004-04-15 MX MXPA04003548A patent/MXPA04003548A/es not_active Application Discontinuation
- 2004-04-15 IS IS7223A patent/IS7223A/is unknown
- 2004-04-15 IS IS7224A patent/IS7224A/is unknown
- 2004-05-11 ZA ZA200403601A patent/ZA200403601B/en unknown
- 2004-05-13 ZA ZA200403690A patent/ZA200403690B/xx unknown
- 2004-05-14 NO NO20041997A patent/NO20041997D0/no not_active Application Discontinuation
- 2004-05-14 NO NO20041996A patent/NO20041996D0/no not_active Application Discontinuation
-
2005
- 2005-09-16 JP JP2005271191A patent/JP2006008704A/ja not_active Withdrawn
- 2005-09-16 JP JP2005271219A patent/JP2006008706A/ja active Pending
-
2009
- 2009-10-09 JP JP2009235793A patent/JP2010006839A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506345A5 (OSRAM) | ||
| JP2005515214A5 (OSRAM) | ||
| JP2007515469A5 (OSRAM) | ||
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| O'Brien et al. | Evaluation of merocyanine 540-sensitized photoirradiation as a means to inactivate enveloped viruses in blood products | |
| WO2002096461A1 (en) | Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients | |
| ES2844629T3 (es) | Tratamiento de la infección por el virus de la hepatitis delta | |
| CN106535895B (zh) | 丁型肝炎病毒感染的治疗 | |
| US10828283B2 (en) | Treatment of hepatitis delta virus infection | |
| US12290509B2 (en) | Treatment of hepatitis delta virus infection | |
| JP2005535588A5 (OSRAM) | ||
| US20220023287A1 (en) | Treatment of hepatitis delta virus infection | |
| JP2016153402A (ja) | Ｃ型肝炎ウイルス感染症の新規治療 | |
| JPWO2021123902A5 (OSRAM) | ||
| JP6110791B2 (ja) | Ｃ型肝炎ウイルス感染症の新規治療 | |
| JP2002371006A (ja) | 肺線維症予防および／または進行防止剤 | |
| RU2006136267A (ru) | Лечение тяжелой внебольничной пневмонии путем введения ингибитора пути тканевого фактора (tfpi) | |
| US20090035273A1 (en) | Combination treatment method with interferon-tau | |
| JP2007532486A5 (OSRAM) | ||
| JP5034944B2 (ja) | インターフェロン作用物質の活性増強剤 | |
| RU2007142192A (ru) | Лечение тяжелой внебольничной пневмонии с помощью введения ингибитора пути тканевого фактора (tfpi) | |
| US20250387377A1 (en) | Treatment of hepatitis delta virus infection | |
| JPH11222440A5 (OSRAM) | ||
| WO2025209478A1 (en) | Methods of treatment warm autoimmune hemolytic anemia using sovleplenib | |
| JP2014510772A (ja) | アリスポリビルを用いたｃ型肝炎ウイルス感染症の治療 |